May 1, 2003British Journal of PharmacologyOpen Access

SR33805, a Ca²⁺ antagonist with length‐dependent Ca²⁺‐sensitizing properties in cardiac myocytes

View Full Paper

Ask AI

Bookmark

Population

Intact and skinned rat ventricular myocytes

Design

Preclinical

Authors

OCOlivier CazorlaCentre National de la Recherche Scientifique ALAlain LacampagneElectrophysiology JFJérémy FauconnierCentre National de la Recherche Scientifique

Discussion

Member takes

Implication

May inform novel inotrope design balancing blockade and sensitization; hypothesis-generating and should not change practice.

Structured PICO

Population

Intact and skinned rat ventricular myocytes

Intervention

SR33805 (low concentrations 10^-8 M and larger doses 10^-6 to 10^-5 M)

Outcome

Contractile properties (cell shortening, Ca2+ transient, action potential, L-type calcium current, maximal Ca2+-activated force, tension-pCa relation)surrogate

SR33805 increases cardiac cell contractile activity through Ca2+-sensitizing effects despite its strong Ca2+-antagonistic properties.

Cite This Study

Cazorla et al. (2003) studied this question.

synapsesocial.com/papers/6a0e8fdfa0467873efc842d9 https://doi.org/10.1038/sj.bjp.0705221

View Full Paper

Ask AI

Bookmark

SR33805, a Ca²⁺ antagonist with length‐dependent Ca²⁺‐sensitizing properties in cardiac myocytes

Discussion

Member takes

Implication

Structured PICO

Cite This Study

SR33805, a Ca²⁺ antagonist with length‐dependent Ca²⁺‐sensitizing properties in cardiac myocytes

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider